Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 4
2011 1
2012 2
2013 6
2014 7
2015 2
2016 2
2017 1
2018 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR() therapeutic protein, for relapsed or refractory NHL patients.
Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK. Pagel JM, et al. Br J Haematol. 2015 Jan;168(1):38-45. doi: 10.1111/bjh.13099. Epub 2014 Aug 22. Br J Haematol. 2015. PMID: 25146490 Free article. Clinical Trial.
CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic. ...The most frequent adverse events were neutropenia, fatigue, nausea, thrombocytopenia, diarrhoea, and periph …
CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized a …
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A. Gopal AK, et al. Invest New Drugs. 2014 Dec;32(6):1213-25. doi: 10.1007/s10637-014-0125-2. Epub 2014 Jun 15. Invest New Drugs. 2014. PMID: 24927856 Free PMC article. Clinical Trial.
PURPOSE: CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic that triggers direct caspase independent apoptosis of malignant B cells and induces antibody-dependent …
PURPOSE: CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel hu …
TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
Robak T, Robak P, Smolewski P. Robak T, et al. Curr Opin Investig Drugs. 2009 Dec;10(12):1383-90. Curr Opin Investig Drugs. 2009. PMID: 19943209 Review.
In addition, TRU-016 demonstrated synergistic or additive activity in NHL cells in combination with rituximab, rapamycin, doxorubicin and bendamustine. ...TRU-016 is a promising therapeutic agent for patients with B-cell lymphoid malignancies, especial …
In addition, TRU-016 demonstrated synergistic or additive activity in NHL cells in combination with rituximab, rapamycin, doxo …
Anti-CD37 antibodies for chronic lymphocytic leukemia.
Robak T, Robak P. Robak T, et al. Expert Opin Biol Ther. 2014 May;14(5):651-61. doi: 10.1517/14712598.2014.890182. Epub 2014 Feb 20. Expert Opin Biol Ther. 2014. PMID: 24555705 Review.
AREAS COVERED: The results of preclinical and early clinical studies suggest that in patients with CLL, newer anti-CD37 agents, otlertuzumab (formerly known as TRU-016), BI 836826, IMGN529 and (177)Lu-tetulomab can be useful in the treatment of this disease. …
AREAS COVERED: The results of preclinical and early clinical studies suggest that in patients with CLL, newer anti-CD37 agents, otlertuzu …
Anti-CD37 targeted immunotherapy of B-Cell malignancies.
Payandeh Z, Noori E, Khalesi B, Mard-Soltani M, Abdolalizadeh J, Khalili S. Payandeh Z, et al. Biotechnol Lett. 2018 Dec;40(11-12):1459-1466. doi: 10.1007/s10529-018-2612-6. Epub 2018 Oct 6. Biotechnol Lett. 2018. PMID: 30293139 Review.
Otlertuzumab more than a TRU(E) toddler in CLL?
Wendtner CM. Wendtner CM. Blood. 2014 Feb 27;123(9):1282-4. doi: 10.1182/blood-2014-01-548560. Blood. 2014. PMID: 24578490 Free article. No abstract available.
Emerging immunological drugs for chronic lymphocytic leukemia.
Robak P, Smolewski P, Robak T. Robak P, et al. Expert Opin Emerg Drugs. 2015 Sep;20(3):423-47. doi: 10.1517/14728214.2015.1046432. Epub 2015 Jul 11. Expert Opin Emerg Drugs. 2015. PMID: 26153226 Review.
The search terms used were alemtuzumab, BI 836826, duvelisib ibrutinib, idelalisib, lenalidomide, monoclonal antibodies, MEDI-551, MOR208, obinutuzumab, ocaratuzumab, ofatumumab, ONO-4059, otlertuzumab, spebrutinib, veltuzumab and XmAb5574 in conjunction with CLL. ...
The search terms used were alemtuzumab, BI 836826, duvelisib ibrutinib, idelalisib, lenalidomide, monoclonal antibodies, MEDI-551, MOR208, o …
Novel agents for chronic lymphocytic leukemia.
Wu M, Akinleye A, Zhu X. Wu M, et al. J Hematol Oncol. 2013 May 16;6:36. doi: 10.1186/1756-8722-6-36. J Hematol Oncol. 2013. PMID: 23680477 Free PMC article. Review.
The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine, ofatumumab, lenalidomide, ibrutinib, idelalisib, veltuzumab, XmAb5574, navitoclax, dasatinib, alvespimycin, and TRU-016. This review summarizes the most current clin …
The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine, ofatumumab, lenalidomide, ibrutinib, id …
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato A, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Eisenfeld AJ, Stromatt SC, Jaeger U. Robak T, et al. Br J Haematol. 2017 Feb;176(4):618-628. doi: 10.1111/bjh.14464. Epub 2016 Dec 15. Br J Haematol. 2017. PMID: 27977057 Free PMC article. Clinical Trial.
Otlertuzumab (TRU-016) is a humanized anti-CD37 protein therapeutic that triggers direct caspase-independent apoptosis of malignant B cells and induces antibody-dependent cell-mediated cytotoxicity. ...Thirty-two patients were treated with otlertuzumab …
Otlertuzumab (TRU-016) is a humanized anti-CD37 protein therapeutic that triggers direct caspase-independent apoptosis …
Refractory chronic lymphocytic leukemia--new therapeutic strategies.
Schnaiter A, Stilgenbauer S. Schnaiter A, et al. Oncotarget. 2010 Nov;1(7):472-82. doi: 10.18632/oncotarget.101103. Oncotarget. 2010. PMID: 21317446 Free PMC article. Review.
The next generation CD20 antibody GA-101 is currently compared to rituximab (R) and will possibly be its more potent successor. Further B-cell antigens are targeted by lumiliximab (CD23), TRU-016 (CD37) and blinatumomab (CD19). Apart from monoclonal antibody therapi …
The next generation CD20 antibody GA-101 is currently compared to rituximab (R) and will possibly be its more potent successor. Further B-ce …
24 results